Perrigo Co. Plc (PRGO)

45.62
NYSE
Prev Close 45.48
Day Low/High 45.27 / 45.85
52 Wk Low/High 40.01 / 63.86
Exchange NYSE
Shares Outstanding 136.48B
Market Cap 6.21B
P/E Ratio 26.38
Div & Yield N.A. (N.A)
Stressed Out: Valeant Shareholders Flee on McKesson Warning

Stressed Out: Valeant Shareholders Flee on McKesson Warning

The drugmaker's shares were hammered Friday on news that the industry is slashing prices.

Stressed Out: Free Cash Flow Is All That Counts Now for Valeant

Stressed Out: Free Cash Flow Is All That Counts Now for Valeant

With a $31 billion debt load, the drugmaker has to show it has the firepower needed to fend off creditors.

Stocks to Worry the Bullish Cabal

Here are some high-profile and widely-held stocks whose charts should concern the bullish cabal:   Netflix Starbucks Disney Tesla Coca-Cola Prudential Ford Valeant Perrigo Dollar Tree Macy's Nike   Note: These stocks represent a broad swath of secto...

Midday Report: American Airlines Falls on Weak August Traffic; U.S. Stocks Climb

Midday Report: American Airlines Falls on Weak August Traffic; U.S. Stocks Climb

Stocks climbed, though worries over how soon the Federal Reserve might hike interest rates kept markets wary.

Perrigo Shares Climb on Starboard Value Investment

Perrigo Shares Climb on Starboard Value Investment

The activist fund says Perrigo's promises over the past year have been "woefully unfulfilled."

Morning Movers: PRGO, MYL, HPQ, MRO, RIG

Morning Movers: PRGO, MYL, HPQ, MRO, RIG

Falling crude oil prices continued to weigh on markets Monday.

Closing Bell: Perrigo Cuts Full-Year Guidance; U.S. Stocks Slip

Closing Bell: Perrigo Cuts Full-Year Guidance; U.S. Stocks Slip

U.S. stocks edged back from records highs set last week as resurfacing supply worries took a chunk out of crude prices.

Trending Tickers: RL, RAD, RIG, PRGO, KLAC

Trending Tickers: RL, RAD, RIG, PRGO, KLAC

Ralph Lauren shares surge on earnings beat amid lethargic market action.

Jim Cramer: Perrigo is Problematic

Jim Cramer: Perrigo is Problematic

Perrigo might have been in more of a decline than the market realized when it turned down Mylan's $26 billion offer for the company last year, says Jim Cramer.

Why I Feel Bearish About the Market

Why I Feel Bearish About the Market

I'm not inclined to make market calls, but the action on my screen is pushing me to a defensive stance.

Don't 'Catch a Falling Knife' with Perrigo

Don't 'Catch a Falling Knife' with Perrigo

The stock's tumbling to near a 52-week low, but charts suggest caution.

Valeant Shares Rally on Outlook, but Analysts Say Debt Worries Still Loom

Valeant Shares Rally on Outlook, but Analysts Say Debt Worries Still Loom

Analysts say Tuesday's earnings beat could spell trouble in terms of coping with its $31 billion worth of debt.

Perrigo upgraded at Deutsche

Looking for Relief From Biotech Pain

Looking for Relief From Biotech Pain

A lost leader in Celgene and a Perrigo rumor have put a scare in the charts.

Valeant, Walgreens CEOs to Tackle 'Speed Bumps'

Valeant, Walgreens CEOs to Tackle 'Speed Bumps'

Papa is set to meet with Walgreens management in hopes of ironing out "speed bumps."

Endo Could Be the Next Activist Target in Generics

Endo Could Be the Next Activist Target in Generics

Problems with mesh products and high leverage might scare away a potential buyer. 

Takeaways and Observations

I was out of the office yesterday, but my take on the session is: "Up, Down, Up, Flat." It was a mixed day in terms of economic data, with potholes everywhere. (You'd have to be blind not to see them.) It was all about retail yet again, and it sure ...

Valeant Whipsawed by Criticism Over Drug Prices and New Leadership

Valeant Whipsawed by Criticism Over Drug Prices and New Leadership

The drugmaker's quest to rebrand itself as a patient-first company is foundering over renewed controversy over drug pricing.

Teva Should Break Out of Droopy Drug Pack

Teva Should Break Out of Droopy Drug Pack

Despite an earnings beat and upbeat outlook, its stock has suffered with other drug makers.

My Takeaways and Observations

Did I mention that the market has no memory from day to day? It was a busy short-side day for me today. Disney (DIS) -- why the mouse is no longing roaring.   On management B.S.  Macy's (M).   Sears (SHLD) is the elephant in the room and a possible ...

There's a Lot to Be Resolved on Perrigo

There's a Lot to Be Resolved on Perrigo

It reports tomorrow, but where will the company ultimately fall this quarter?

Papa and His Brand New Gig (at VRX)

"Papa's in the swing. He ain't too hip about that new breed babe. He ain't no drag. Papa's got a brand new bag." -- James Brown, Papa's Got a Brand New Bag Jim "El Capitan" Cramer clearly outlined the key risks facing Valeant Pharmaceuticals (VRX) t...

Cramer: The World Is Gunning for Valeant

Cramer: The World Is Gunning for Valeant

And Joe Papa can't stop the world. 

Jim Cramer: Allergan CEO Brent Saunders Is Doing a Great Job

Jim Cramer: Allergan CEO Brent Saunders Is Doing a Great Job

Jim Cramer thinks Allergan CEO Brent Saunders has put together a world class company.

Cramer on Valeant’s New CEO Joseph Papa

Cramer on Valeant’s New CEO Joseph Papa

New Valeant CEO and former Perrigo CEO Joseph Papa will be joining TheStreet's Jim Cramer on "Mad Money" tonight.

Perrigo Bears Turn Aggressive

Perrigo Bears Turn Aggressive

Perrigo could have an oversold bounce at any time as bears turn aggressive, but nothing right now indicates a price bottom.

Avoid Valeant (Redux)

I noted in my previous missive that my ursine friend Jim Chanos spoke out on CNBC's Fast Money Halftime show today in favor of shorting the Chinese stock market. Well, he also just expressed skepticism on Valeant Pharmaceuticals (VRX) -- another vie...

My Diagnosis of Valeant Pharmaceuticals

"Valeant, of course, was a sewer ... [and its directors deserve] all the opprobrium they are getting." -- Charlie Munger, vice chairman of Berkshire Hathaway (BRK.A, BRK.B), at this weekend's annual Berkshire shareholder meeting Pershing Square's Bi...

It's Scary Down There: Buying at the Lows

It's Scary Down There: Buying at the Lows

Get paid very well for making the 'uncomfortable' play others are afraid to take. 

It's Scary Down There: Buying at the Lows

It's Scary Down There: Buying at the Lows

Get paid very well for making the 'uncomfortable' play others are afraid to take.